Cart
sales@molnova.com
KCL-286
CAS No. 1952276-71-9
KCL-286( —— )
Catalog No. M37200 CAS No. 1952276-71-9
KCL-286 is an orally available and potent retinoic acid receptor beta agonist for the amelioration of spinal cord injury (SCI).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 123 | Get Quote |
|
| 5MG | 187 | Get Quote |
|
| 10MG | 302 | Get Quote |
|
| 25MG | 615 | Get Quote |
|
| 50MG | 984 | Get Quote |
|
| 100MG | 1305 | Get Quote |
|
| 200MG | 1755 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameKCL-286
-
NoteResearch use only, not for human use.
-
Brief DescriptionKCL-286 is an orally available and potent retinoic acid receptor beta agonist for the amelioration of spinal cord injury (SCI).
-
DescriptionAnticancer agent 168 is an orally active retinoic acid receptor (RAR/RXR) beta2 agonist with ameliorating effects on spinal cord injury (SCI).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetRetinoid Receptor
-
RecptorRetinoid Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1952276-71-9
-
Formula Weight334.33
-
Molecular FormulaC19H14N2O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(O)C=1C=CC(=CC1)C2=NOC(=N2)C=3OC=4C(C3)=C(C=CC4C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Goncalves MB, et al. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants. Br J Clin Pharmacol. 2023 Jul 15..?
molnova catalog
related products
-
AC-55649
AC-55649 is a potent and highly isoform-selective agonist of the human RARβ2 receptor, characterized by a pEC50 of 6.9.
-
trifarotene
trifarotene is a potent and selective RARγ agonist with 65-fold and 16-fold selectivitiy for the RARγ (EC50=7.7 nM) over RARα (EC50=500 nM) and RARβ (EC50=125 nM).
-
LG-100064
LG-100064 is an agonist of retinoid-X-receptor (RXR)(EC50s of 330 nM, 200 nM, and 260 nM for RXRα, RXRβ and RXRγ)LG-100064 shows no effect on RARα/β/γ (EC50, >10000 nM).LG-100064 (3-Methyl-TTNCB) is a retinoid-X-receptor (RXR) agonist, with EC50s of 330 nM, 200 nM, and 260 nM for RXRα, RXRβ and RXRγ.
